Uniphar (LON:UPR) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of Uniphar (LON:UPR) in a research report sent to investors on Wednesday, Marketbeat Ratings reports. They currently have a GBX 310 ($4.08) price target on the stock.

Uniphar Price Performance

Uniphar stock opened at GBX 221 ($2.91) on Wednesday. The company’s 50 day simple moving average is GBX 217.21 and its 200-day simple moving average is GBX 222.39. The company has a market capitalization of £603.37 million, a price-to-earnings ratio of 1,578.57 and a beta of 0.77. Uniphar has a 1 year low of GBX 178 ($2.34) and a 1 year high of GBX 256 ($3.37). The company has a debt-to-equity ratio of 114.50, a quick ratio of 0.60 and a current ratio of 0.88.

Uniphar Cuts Dividend

The business also recently declared a dividend, which will be paid on Friday, October 4th. Stockholders of record on Thursday, September 12th will be paid a €0.01 ($0.01) dividend. This represents a dividend yield of 0.25%. The ex-dividend date of this dividend is Thursday, September 12th. Uniphar’s dividend payout ratio (DPR) is 1,428.57%.

Uniphar Company Profile

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally. The company operates through three divisions: Medtech, Pharma, and Supply Chain & Retail. The Medtech division offers outsourced sales; and marketing, distribution, and support services to medical device manufacturers.